picture alliance/Getty Images Merck rose about 3% in early trading Tuesday after crushing Wall Street estimates for second-quarter earnings and announcing rapid sales growth for its Keytruda cancer treatment. The cancer drug sold $2.63 billion in the second quarter, a nearly-$1 billion increase from the year ago period. Keytruda is now on pace to generate […]